Thesimmering proxy fight at Amylin will only benefit shareholders, according to Forbes.With activist shareholder Carl Icahn taking a 10 percent stake in thepharmaceuticals company, the likelihood of the company being acquired is nearcertain.
Icahn’s group, along with investment group Eastbourne Capital,will likely implant a new slate of directors in order to facilitate a companysale. Amylin shares have risen 15 percent since the two investors began theirproxy efforts.